The Mahamaya Lifesciences IPO has generated considerable buzz among investors, especially those tracking the Mahamaya Lifesciences IPO GMP (Grey Market Premium) ahead of its listing. With its entry into the public markets, the company aims to raise funds to fuel its next phase of growth in the pharmaceutical and life sciences sector. Let’s take a detailed look at the IPO size, subscription dates, GMP trends, and key financial highlights.
Mahamaya Lifesciences IPO Overview
The Mahamaya Lifesciences IPO is a book-built issue worth ₹70.44 crore. It includes both a fresh issue and an offer for sale (OFS):
- Fresh Issue: 0.56 crore shares aggregating to ₹64.28 crore
- Offer for Sale (OFS): 0.05 crore shares aggregating to ₹6.16 crore
The company intends to use the proceeds from the fresh issue to strengthen its R&D facilities, meet working capital requirements, and fund expansion plans.
Mahamaya Lifesciences IPO Important Dates
Event | Date |
IPO Open Date | November 11, 2025 |
IPO Close Date | November 13, 2025 |
Basis of Allotment | November 14, 2025 |
Refunds Initiation | November 17, 2025 |
Credit of Shares | November 17, 2025 |
Listing Date | November 18, 2025 |
The IPO will list on the BSE SME platform, with a tentative listing date set for November 18, 2025.
? Mahamaya Lifesciences IPO Price Band and Lot Size
- Price Band: ₹108 – ₹114 per share
- Lot Size: 1,200 shares per lot
For retail investors, the minimum investment required is ₹2,73,600 (based on the upper price band and minimum lot size of 2 lots).
Investor Category | Lot Size | Shares | Investment (Approx.) |
Retail Investors | 2 lots | 2,400 shares | ₹2,73,600 |
HNI Investors | 3 lots | 3,600 shares | ₹4,10,400 |
This IPO targets both retail and high-net-worth investors looking for exposure in the growing pharmaceutical and life sciences segment.
Mahamaya Lifesciences IPO GMP (Grey Market Premium)
The Mahamaya Lifesciences IPO GMP is a key metric for investors tracking the grey market trend before listing. The GMP represents the premium that shares are commanding in the unofficial market, reflecting investor sentiment and expected listing performance.
As per the latest reports, the Mahamaya Lifesciences IPO GMP is trending around ₹20–₹25 per share, suggesting a listing gain of approximately 15–20% over the upper issue price of ₹114. This indicates strong investor interest in the SME segment, particularly in the healthcare sector.
However, investors should note that GMP figures are indicative and can fluctuate based on subscription strength, market volatility, and overall sentiment in the IPO space.
About Mahamaya Lifesciences Limited
Mahamaya Lifesciences Limited is engaged in the manufacturing and marketing of pharmaceutical formulations and life science-based products. The company focuses on the development of innovative, high-quality, and affordable medicines that cater to both domestic and international markets.
Its diversified portfolio includes formulations used in various therapeutic areas, such as anti-infectives, cardiovascular, nutraceuticals, and pain management segments. With a commitment to R&D, Mahamaya Lifesciences aims to introduce advanced drug formulations and expand its presence across the healthcare ecosystem.
Objectives of the IPO
The proceeds from the Mahamaya Lifesciences IPO will be utilized for the following purposes:
- Expansion of existing manufacturing facilities
- Enhancement of research and development capabilities
- Funding working capital requirements
- General corporate purposes
These steps are expected to improve operational efficiency, boost production capacity, and support long-term business sustainability.
Should You Invest in Mahamaya Lifesciences IPO?
Investors are showing interest in this IPO due to the company’s strong presence in the life sciences industry and positive GMP movement. The pharmaceutical sector continues to attract attention for its growth potential, making Mahamaya Lifesciences a noteworthy addition to the SME IPO space.
Reasons to consider investing:
- Consistent financial performance with growth potential in the pharma space
- Strong focus on innovation and R&D expansion
- Attractive price band and positive GMP trend
- Experienced management team with a clear growth roadmap
However, being a BSE SME IPO, liquidity may be relatively limited compared to mainboard listings. Investors should assess their risk appetite before subscribing.
Conclusion
The Mahamaya Lifesciences IPO offers investors an opportunity to participate in India’s growing pharmaceutical and life sciences market. With a total issue size of ₹70.44 crore, a price band of ₹108–₹114, and a listing on BSE SME, the IPO has already caught the attention of retail and HNI investors alike.
The current Mahamaya Lifesciences IPO GMP indicates optimistic market sentiment and the potential for healthy listing gains. Still, investors are advised to perform due diligence and consider long-term fundamentals before making an investment decision.
